Key Takeaways
- Domestic volume holds up, international drags: Like-to-like domestic volume grew 8%, but a 12% international decline pulled overall core growth down to ~6%.
- Strategic investments surge 61%: All four subsidiaries delivered strong volume and value growth, with TMC rebounding north of 20% after two difficult years.
- Gross margin under twin pressure: Input costs rose 360 bps, split roughly 200 bps from West Asia conflict-driven commodity inflation and 160 bps from the lower-margin mix of acquired businesses.
- PAT down 16% on tax normalization: The drop reflects a return to a ~25% effective tax rate after prior-year fiscal benefits, not operational deterioration.
- What to watch next quarter: Whether the promised pricing actions offset the input cost headwind, whether OTC pain management exports resume, and whether the international business stabilizes as guided.
Domestic Performance & Category Trends
- Hair & Scalp care led with 11% growth: Navratna Cool Oil delivered strong double-digit growth, Kesh King grew mid- to high single digits with some base effect, and 7 Oils in One posted robust growth.
- Skin Care grew 3% with regional divergence: The talc portfolio delivered high single-digit growth and management expects a recovery to FY25 revenue levels this year; Male Grooming and BoroPlus each posted low single-digit growth.
- Healthcare grew 2% on OTC strength: The OTC portfolio grew in high teens while the Medico range posted single-digit growth; Zandu delivered strong double-digit growth driven by new positioning campaigns for Pancharishta and Nityam.
- Organized channels grew 19% like-to-like: Modern trade and e-commerce sustained strong momentum; quick commerce now accounts for 35% of e-commerce sales.
- Kesh King trajectory: Growth was mid- to high single-digit this quarter with some base effect impact; management expects double-digit growth by year-end, supported by new launches mostly in the D2C space.
Mohan Goenka: "I'm not worried for the whole year, Arnab, very honestly. I think the next few quarters should be relatively better than this."
Strategic Investments: The Growth Engine
- 61% like-to-like growth across all four subsidiaries: Growth was driven in both volume and value; TMC grew well north of 20% after struggling for two years; Axiom is benefiting from initiatives started in the prior year.
- Gross margins are healthy across the portfolio: All four start-ups are above 55% gross margin; TMC is north of 60%, Brillare and IncNut are north of 70%, and Axiom is slightly lower but above 50%.
- Aggregate at EBITDA neutral/breakeven: Losses reduced this quarter compared to last year; some brands are at different stages of growth and management does not want to sacrifice momentum for near-term profitability.
- FY27 revenue target: ₹750–800 crores: This implies 20–30% year-on-year growth; the long-term target is high single-digit EBITDA margin at the 3-year point.
- Repeatable model claim: A central team under Dhruv Aggarwal runs the strategic investments group out of Gurgaon, with senior talent as CEOs for each individual business; management says every brand has grown under this model.
Dhruv Aggarwal: "I think net-net, there is a long-term target, 2, 3-year target where we will get to a good healthy amount of profitability. But if there is momentum right now, then we don't want to give up on that because any growth in our top line at start-ups that are between INR100 crores to INR300 crores will only offset our fixed cost and help us in the long term."
International Business: The Drag
- 12% decline driven by West Asia conflict: OTC pain management products produced in India remain unable to move out due to supply chain disruptions; personal care products produced in UAE, Germany, and Thailand were less affected.
- Hefty orders stuck, resolution in sight: Management is trying to secure ministry approvals and expects to move some product from India in a few days; once sorted, supply reinstatement to markets should be fully resolved.
- Decline is now done, recovery expected from Q3: International business strategies have been realigned over the last 1–2 quarters during the disruptions; significant growth is expected from the third and fourth quarters.
Mohan Goenka: "And on the international front, I think the decline, this is now done. Most likely, you will see a significant growth coming in from the third and the fourth quarter because we have got -- we have realigned our -- a lot of international business strategies have been realigned in the last 1, 2 quarters when all these disruptions were happening."
Margins & Cost Pressures
- 360 bps total input cost increase: ~200 bps from West Asia conflict-driven commodity inflation (higher crude oil, packaging material costs) and ~160 bps from business mix change as acquired businesses carry lower margins.
- EBITDA grew 6% to ₹226 crores despite the pressure: Cost management initiatives provided resilience; aggressive price increases have been taken wherever needed and further pricing actions are planned to more than offset the absolute input cost increase during the financial year.
- Management committed that overall margins do not come down: The pressure is seen as short-term and linked to the West Asia conflict; confidence in gaining in coming quarters rests on pricing actions in core businesses.
- Other income elevated: Standalone other income of ₹53 crores included a ₹32 crore dividend from an international subsidiary, a non-recurring boost.
Mohan Goenka: "We can't just rely on certain markets where margins are very high and the growth is coming from different -- so there has to be a good balance, okay? But despite of all this, we are committed that our margins don't come down."
Strategic Initiatives & Reporting Change
- Reporting framework transition: The company is moving from brand-wise reporting to category-wise reporting, reflecting increasing scale and diversification; management cited the growing number of brands and a pipeline of more acquisitions as the rationale.
- Three operational initiatives underway, all to complete this fiscal year: (1) enhancing supply chain planning, inventory management and distribution visibility; (2) Sales code AI deployment for sales organization productivity; (3) an analytical hub creating a single enterprise-wide platform for data analytics and AI.
- New launches across portfolios: Kesh King launches planned mostly in D2C; Zandu OTC business launching new products using sales team strength and distribution; Medico business seeing good response to innovative launches.
Mohan Goenka: "Someday we had to start this because with so many brands coming in, it was not possible for us to give brand-wise information... And there are more brands in the pipeline we are looking for. So how do we keep on reporting brand-wise information."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Input cost recovery | Pricing actions to more than offset absolute input cost increase | During FY27 |
| International business recovery | Significant growth expected following strategy realignment | Q3 and Q4 FY27 |
| Talcum powder revenue recovery | Return to FY25 revenue numbers; substantially high numbers expected | Current quarter and full year |
| Kesh King growth | Double-digit growth | By year-end FY27 |
| Strategic investments revenue | ₹750–800 crores, growing 20–30% YoY | FY27 |
| Strategic initiatives completion | Supply chain, Sales code AI, analytical hub | During FY27 |
| Tax rate | ~25–26% | FY27 |
| OTC business growth | Double-digit growth to continue; winter season plans being prepared | Rest of FY27 |
| Overall margin commitment | Margins not to come down despite faster growth in lower-margin businesses | Ongoing |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Consolidated revenue | ₹1,039 cr, +15% YoY |
| Domestic business revenue growth | +20% reported, +12% like-to-like with +8% volume growth |
| EBITDA | ₹226 cr, +6% YoY |
| Profit before tax | ₹195 cr, +4% YoY |
| Profit after tax | ₹137 cr, -16% YoY due to normalization of effective tax rate |
| Gross margin impact from input costs | +360 bps increase in input cost: ~200 bps from West Asia conflict, ~160 bps from business mix change |
| Effective tax rate | 28–29% in Q1, normal rate expected around 25–26% for FY27 |
| Hair and Scalp care growth | +11% YoY |
| Skin Care growth | +3% YoY |
| Healthcare growth | +2% YoY |
| Strategic investment portfolio growth | +61% like-to-like YoY, now 18% of domestic business |
| Strategic investment portfolio revenue | ~₹160 cr in Q1, expected ₹750–800 cr for full year |
| International business growth | -12% YoY, primarily due to West Asia conflict disruptions |
| Organized channels growth | +19% like-to-like YoY, now 32% of domestic business |
| Quick commerce share of e-com | 35% of e-com business |